67,354 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 67,354 shares of the company’s stock, valued at approximately $172,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Swiss National Bank grew its stake in ImmunityBio by 1.5% in the fourth quarter. Swiss National Bank now owns 274,000 shares of the company’s stock valued at $701,000 after acquiring an additional 4,000 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of ImmunityBio by 20.4% in the 4th quarter. Teacher Retirement System of Texas now owns 41,742 shares of the company’s stock worth $107,000 after purchasing an additional 7,067 shares in the last quarter. Commonwealth Equity Services LLC grew its position in ImmunityBio by 40.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 28,955 shares of the company’s stock valued at $74,000 after purchasing an additional 8,380 shares during the period. Alliancebernstein L.P. increased its stake in ImmunityBio by 4.1% during the 4th quarter. Alliancebernstein L.P. now owns 214,030 shares of the company’s stock valued at $548,000 after purchasing an additional 8,500 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in ImmunityBio by 32.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 38,900 shares of the company’s stock valued at $100,000 after purchasing an additional 9,622 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a report on Monday. D. Boral Capital reiterated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Monday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $2.51 on Wednesday. The stock has a market capitalization of $2.22 billion, a P/E ratio of -2.73 and a beta of 0.33. The company has a 50-day moving average price of $2.66 and a 200-day moving average price of $3.35. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $9.16.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The firm had revenue of $16.52 million for the quarter, compared to analysts’ expectations of $17.50 million. As a group, equities research analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.